呼吸器疾患ワクチンの市場規模、シェア、動向分析レポート：タイプ別、感染症別、年齢層別、流通チャネル別、地域別、セグメント予測、2025～2030年

呼吸器疾患ワクチン市場の成長と動向

Grand View Research, Inc.の最新レポートによると、呼吸器疾患ワクチン市場規模は2030年までに703億米ドルに達し、2025～2030年にかけてCAGR 2.90％で拡大すると推定されています。

呼吸器疾患ワクチン市場の成長は、ワクチン接種の重要性に関する意識の高まり、呼吸器感染症の発生率の上昇、ワクチン技術の進歩に起因しています。さらに、COVID-19のパンデミックは、呼吸器系ワクチンの重要性に大きな牽引力をもたらし、市場をさらに加速させています。

呼吸器系ワクチン、特にインフルエンザや肺炎をターゲットとしたワクチンは、ヘルスケアシステムの負担を軽減し、COVID-19との重複感染リスクを最小限に抑えるために不可欠です。ウイルスの蔓延を防ぎ、アウトブレイクの発生を防ぐため、ヘルスケア提供者はインフルエンザなどの呼吸器病原体から個人を守るワクチン接種に注力しています。ここ数年、呼吸器系ワクチン市場は、ワクチン技術の進歩、特にSARS-CoV-2を標的としたワクチンの開発により、大きく成長しています。COVID-19ワクチンの開発、承認、配備の成功は、呼吸器系の脅威に迅速に対応する科学界の能力を実証し、呼吸器系ワクチンの研究開発における将来の進歩への道を開きました。

さらに、インフルエンザワクチンの入手可能性、普及、実施を監視するための国レベル、世界レベルでの政府の支援と監視は、市場の成長を促進する重要な要因です。さらに、新規ワクチンの市場導入に重点を置く著名な主要企業による投資の増加が、市場の成長に寄与しています。例えば、Pfizerは、mRNAベースのインフルエンザワクチンの第3相臨床試験を2022年9月に開始する計画を明らかにしました。この試験には、米国の18歳以上の2万5,000人のコホートが参加する予定です。

さらに、様々な呼吸器疾患ワクチンの開発・製剤化に携わる主な企業は、新規ワクチンの開発や市場での競争力維持のため、共同研究や提携に注力しています。加えて、植物由来の医薬品が提供する自然療法に対する関心の高まりが、予測期間中に市場を押し上げると予想されます。さらに、医薬品需要の高まりに対応するため、多くの企業が地理的拡大や流通に関与しています。例えば、2023年5月、Pfizer Inc.は、60歳以上の高齢者層におけるRSVによる下気道疾患の予防を目的としたRSVワクチンABRYSVOのFDA承認を取得しました。

呼吸器疾患ワクチン市場レポートハイライト

• タイプ別では、ウイルス性呼吸器疾患の有病率の増加により、ウイルス性ワクチン分野が2024年に54.84%の最大市場シェアを占めました。
• 年齢層別では、小児向けのワクチン製剤の増加により、小児セグメントが予測期間中に最も速い成長率を示すと予想されます。
• 感染症別では、COVID-19ウイルスの蔓延を阻止するワクチン開発の必要性が高まっていることから、2024年にはCOVID-19セグメントが40.03%の最大市場シェアを占めました。
• 同市場で事業を展開する主要企業は、その存在感を維持するため、常に地理的拡大と製品上市に注力しています。
• 北米の呼吸器疾患ワクチン市場は予測期間中に力強い成長が見込まれますが、これは主要プレイヤーの存在、ヘルスケアインフラの台頭、慢性疾患の症例増加、適切なワクチン接種サービスの利用が可能であることに起因しています。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 呼吸器疾患ワクチン市場の変数、動向、範囲

• 市場イントロダクション/系統展望
• 市場規模と成長展望
• 市場力学
  • 市場促進要因分析
  • 市場抑制要因分析
• 呼吸器疾患ワクチン市場分析ツール
  • ポーター分析
  • PESTEL分析

第4章 呼吸器疾患ワクチン市場：タイプ別、推定・動向分析

• セグメントダッシュボード
• 呼吸器疾患ワクチン市場：タイプ変動分析、2024年および2030年
• ウイルスワクチン
• 細菌ワクチン
• 混合ワクチン

第5章 呼吸器疾患ワクチン市場：年齢層別、推定・動向分析

• セグメントダッシュボード
• 呼吸器疾患ワクチン市場：年齢層変動分析、2024年および2030年
• 小児
• 成人

第6章 呼吸器疾患ワクチン市場：感染症別、推定・動向分析

• セグメントダッシュボード
• 呼吸器疾患ワクチン市場：感染症変動分析、2024年および2030年
• COVID-19
• インフルエンザ
• 呼吸器合胞体ウイルス（RSV）
• 肺炎
• その他

第7章 呼吸器疾患ワクチン市場：流通チャネル別、推定・動向分析

• セグメントダッシュボード
• 呼吸器疾患ワクチン市場：流通チャネル変動分析、2024年および2030年
• 病院・薬局
• 政府サプライヤー
• その他

第8章 呼吸器疾患ワクチン市場：地域別、推定・動向分析

• 呼吸器疾患ワクチン市場シェア：地域別、2024年および2030年
• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • 英国
  • ドイツ
  • フランス
  • イタリア
  • スペイン
  • デンマーク
  • スウェーデン
  • ノルウェー
• アジア太平洋
  • 日本
  • 中国
  • インド
  • オーストラリア
  • 韓国
  • タイ
• ラテンアメリカ
  • ブラジル
  • アルゼンチン
• 中東およびアフリカ
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • クウェート

第9章 競合情勢

• 主要市場参入企業による最近の動向と影響分析
• 企業分類
• 企業ヒートマップ分析
• 企業プロファイル
  • GSK plc.
  • Johnson &Johnson Services, Inc.
  • Pfizer Inc.
  • Sanofi
  • Serum Institute of India Pvt. Ltd.
  • SINOVAC
  • Bavarian Nordic
  • Merck &Co., Inc.
  • AstraZeneca
  • EMERGENT
  • Novavax
  • INOVIO Pharmaceuticals
  • Moderna, Inc.

List of Tables

• Table 1 List of Secondary Sources
• Table 2 List of Abbreviation
• Table 3 Global Respiratory Disease Vaccine Market, By Region, 2018 - 2030 (USD Million)
• Table 4 Global Respiratory Disease Vaccine Market, By Type, 2018 - 2030 (USD Million)
• Table 5 Global Respiratory Disease Vaccine Market, By Age Group, 2018 - 2030 (USD Million)
• Table 6 Global Respiratory Disease Vaccine Market, By Infection, 2018 - 2030 (USD Million)
• Table 7 Global Respiratory Disease Vaccine Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 8 North America Respiratory Disease Vaccine Market, By Country, 2018 - 2030 (USD Million)
• Table 9 North America Respiratory Disease Vaccine Market, By Type, 2018 - 2030 (USD Million)
• Table 10 North America Respiratory Disease Vaccine Market, By Age Group, 2018 - 2030 (USD Million)
• Table 11 North America Respiratory Disease Vaccine Market, By Infection, 2018 - 2030 (USD Million)
• Table 12 North America Respiratory Disease Vaccine Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 13 U.S. Respiratory Disease Vaccine Market, By Type, 2018 - 2030 (USD Million)
• Table 14 U.S. Respiratory Disease Vaccine Market, By Age Group, 2018 - 2030 (USD Million)
• Table 15 U.S. Respiratory Disease Vaccine Market, By Infection, 2018 - 2030 (USD Million)
• Table 16 U.S. Respiratory Disease Vaccine Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 17 Canada Respiratory Disease Vaccine Market, By Type, 2018 - 2030 (USD Million)
• Table 18 Canada Respiratory Disease Vaccine Market, By Age Group, 2018 - 2030 (USD Million)
• Table 19 Canada Respiratory Disease Vaccine Market, By Infection, 2018 - 2030 (USD Million)
• Table 20 Canada Respiratory Disease Vaccine Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 21 Mexico Respiratory Disease Vaccine Market, By Type, 2018 - 2030 (USD Million)
• Table 22 Mexico Respiratory Disease Vaccine Market, By Age Group, 2018 - 2030 (USD Million)
• Table 23 Mexico Respiratory Disease Vaccine Market, By Infection, 2018 - 2030 (USD Million)
• Table 24 Mexico Respiratory Disease Vaccine Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 25 Europe Respiratory Disease Vaccine Market, By Country, 2018 - 2030 (USD Million)
• Table 26 Europe Respiratory Disease Vaccine Market, By Type, 2018 - 2030 (USD Million)
• Table 27 Europe Respiratory Disease Vaccine Market, By Age Group, 2018 - 2030 (USD Million)
• Table 28 Europe Respiratory Disease Vaccine Market, By Infection, 2018 - 2030 (USD Million)
• Table 29 Europe Respiratory Disease Vaccine Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 30 Germany Respiratory Disease Vaccine Market, By Type, 2018 - 2030 (USD Million)
• Table 31 Germany Respiratory Disease Vaccine Market, By Age Group, 2018 - 2030 (USD Million)
• Table 32 Germany Respiratory Disease Vaccine Market, By Infection, 2018 - 2030 (USD Million)
• Table 33 Germany Respiratory Disease Vaccine Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 34 UK Respiratory Disease Vaccine Market, By Type, 2018 - 2030 (USD Million)
• Table 35 UK Respiratory Disease Vaccine Market, By Age Group, 2018 - 2030 (USD Million)
• Table 36 UK Respiratory Disease Vaccine Market, By Infection, 2018 - 2030 (USD Million)
• Table 37 UK Respiratory Disease Vaccine Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 38 France Respiratory Disease Vaccine Market, By Type, 2018 - 2030 (USD Million)
• Table 39 France Respiratory Disease Vaccine Market, By Age Group, 2018 - 2030 (USD Million)
• Table 40 France Respiratory Disease Vaccine Market, By Infection, 2018 - 2030 (USD Million)
• Table 41 France Respiratory Disease Vaccine Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 42 Italy Respiratory Disease Vaccine Market, By Type, 2018 - 2030 (USD Million)
• Table 43 Italy Respiratory Disease Vaccine Market, By Age Group, 2018 - 2030 (USD Million)
• Table 44 Italy Respiratory Disease Vaccine Market, By Infection, 2018 - 2030 (USD Million)
• Table 45 Italy Respiratory Disease Vaccine Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 46 Spain Respiratory Disease Vaccine Market, By Type, 2018 - 2030 (USD Million)
• Table 47 Spain Respiratory Disease Vaccine Market, By Age Group, 2018 - 2030 (USD Million)
• Table 48 Spain Respiratory Disease Vaccine Market, By Infection, 2018 - 2030 (USD Million)
• Table 49 Spain Respiratory Disease Vaccine Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 50 Denmark Respiratory Disease Vaccine Market, By Type, 2018 - 2030 (USD Million)
• Table 51 Denmark Respiratory Disease Vaccine Market, By Age Group, 2018 - 2030 (USD Million)
• Table 52 Denmark Respiratory Disease Vaccine Market, By Infection, 2018 - 2030 (USD Million)
• Table 53 Denmark Respiratory Disease Vaccine Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 54 Sweden Respiratory Disease Vaccine Market, By Type, 2018 - 2030 (USD Million)
• Table 55 Sweden Respiratory Disease Vaccine Market, By Age Group, 2018 - 2030 (USD Million)
• Table 56 Sweden Respiratory Disease Vaccine Market, By Infection, 2018 - 2030 (USD Million)
• Table 57 Sweden Respiratory Disease Vaccine Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 58 Norway Respiratory Disease Vaccine Market, By Type, 2018 - 2030 (USD Million)
• Table 59 Norway Respiratory Disease Vaccine Market, By Age Group, 2018 - 2030 (USD Million)
• Table 60 Norway Respiratory Disease Vaccine Market, By Infection, 2018 - 2030 (USD Million)
• Table 61 Norway Respiratory Disease Vaccine Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 62 Asia Pacific Respiratory Disease Vaccine Market, By Country, 2018 - 2030 (USD Million)
• Table 63 Asia Pacific Respiratory Disease Vaccine Market, By Type, 2018 - 2030 (USD Million)
• Table 64 Asia Pacific Respiratory Disease Vaccine Market, By Age Group, 2018 - 2030 (USD Million)
• Table 65 Asia Pacific Respiratory Disease Vaccine Market, By Infection, 2018 - 2030 (USD Million)
• Table 66 Asia Pacific Respiratory Disease Vaccine Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 67 Japan Respiratory Disease Vaccine Market, By Type, 2018 - 2030 (USD Million)
• Table 68 Japan Respiratory Disease Vaccine Market, By Age Group, 2018 - 2030 (USD Million)
• Table 69 Japan Respiratory Disease Vaccine Market, By Infection, 2018 - 2030 (USD Million)
• Table 70 Japan Respiratory Disease Vaccine Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 71 China Respiratory Disease Vaccine Market, By Type, 2018 - 2030 (USD Million)
• Table 72 China Respiratory Disease Vaccine Market, By Age Group, 2018 - 2030 (USD Million)
• Table 73 China Respiratory Disease Vaccine Market, By Infection, 2018 - 2030 (USD Million)
• Table 74 China Respiratory Disease Vaccine Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 75 India Respiratory Disease Vaccine Market, By Type, 2018 - 2030 (USD Million)
• Table 76 India Respiratory Disease Vaccine Market, By Age Group, 2018 - 2030 (USD Million)
• Table 77 India Respiratory Disease Vaccine Market, By Infection, 2018 - 2030 (USD Million)
• Table 78 India Respiratory Disease Vaccine Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 79 South Korea Respiratory Disease Vaccine Market, By Type, 2018 - 2030 (USD Million)
• Table 80 South Korea Respiratory Disease Vaccine Market, By Age Group, 2018 - 2030 (USD Million)
• Table 81 South Korea Respiratory Disease Vaccine Market, By Infection, 2018 - 2030 (USD Million)
• Table 82 South Korea Respiratory Disease Vaccine Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 83 Australia Respiratory Disease Vaccine Market, By Type, 2018 - 2030 (USD Million)
• Table 84 Australia Respiratory Disease Vaccine Market, By Age Group, 2018 - 2030 (USD Million)
• Table 85 Australia Respiratory Disease Vaccine Market, By Infection, 2018 - 2030 (USD Million)
• Table 86 Australia Respiratory Disease Vaccine Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 87 Thailand Respiratory Disease Vaccine Market, By Type, 2018 - 2030 (USD Million)
• Table 88 Thailand Respiratory Disease Vaccine Market, By Age Group, 2018 - 2030 (USD Million)
• Table 89 Thailand Respiratory Disease Vaccine Market, By Infection, 2018 - 2030 (USD Million)
• Table 90 Thailand Respiratory Disease Vaccine Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 91 Latin America Respiratory Disease Vaccine Market, By Country, 2018 - 2030 (USD Million)
• Table 92 Latin America Respiratory Disease Vaccine Market, By Type, 2018 - 2030 (USD Million)
• Table 93 Latin America Respiratory Disease Vaccine Market, By Age Group, 2018 - 2030 (USD Million)
• Table 94 Latin America Respiratory Disease Vaccine Market, By Infection, 2018 - 2030 (USD Million)
• Table 95 Latin America Respiratory Disease Vaccine Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 96 Brazil Respiratory Disease Vaccine Market, By Type, 2018 - 2030 (USD Million)
• Table 97 Brazil Respiratory Disease Vaccine Market, By Age Group, 2018 - 2030 (USD Million)
• Table 98 Brazil Respiratory Disease Vaccine Market, By Infection, 2018 - 2030 (USD Million)
• Table 99 Brazil Respiratory Disease Vaccine Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 100 Argentina Respiratory Disease Vaccine Market, By Type, 2018 - 2030 (USD Million)
• Table 101 Argentina Respiratory Disease Vaccine Market, By Age Group, 2018 - 2030 (USD Million)
• Table 102 Argentina Respiratory Disease Vaccine Market, By Infection, 2018 - 2030 (USD Million)
• Table 103 Argentina Respiratory Disease Vaccine Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 104 Middle East & Africa Respiratory Disease Vaccine Market, By Country, 2018 - 2030 (USD Million)
• Table 105 Middle East & Africa Respiratory Disease Vaccine Market, By Type, 2018 - 2030 (USD Million)
• Table 106 Middle East & Africa Respiratory Disease Vaccine Market, By Age Group, 2018 - 2030 (USD Million)
• Table 107 Middle East & Africa Respiratory Disease Vaccine Market, By Infection, 2018 - 2030 (USD Million)
• Table 108 Middle East & Africa Respiratory Disease Vaccine Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 109 Saudi Arabia Respiratory Disease Vaccine Market, By Type, 2018 - 2030 (USD Million)
• Table 110 Saudi Arabia Respiratory Disease Vaccine Market, By Age Group, 2018 - 2030 (USD Million)
• Table 111 Saudi Arabia Respiratory Disease Vaccine Market, By Infection, 2018 - 2030 (USD Million)
• Table 112 Saudi Arabia Respiratory Disease Vaccine Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 113 South Africa Respiratory Disease Vaccine Market, By Type, 2018 - 2030 (USD Million)
• Table 114 South Africa Respiratory Disease Vaccine Market, By Age Group, 2018 - 2030 (USD Million)
• Table 115 South Africa Respiratory Disease Vaccine Market, By Infection, 2018 - 2030 (USD Million)
• Table 116 South Africa Respiratory Disease Vaccine Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 117 UAE Respiratory Disease Vaccine Market, By Type, 2018 - 2030 (USD Million)
• Table 118 UAE Respiratory Disease Vaccine Market, By Age Group, 2018 - 2030 (USD Million)
• Table 119 UAE Respiratory Disease Vaccine Market, By Infection, 2018 - 2030 (USD Million)
• Table 120 UAE Respiratory Disease Vaccine Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 121 Kuwait Respiratory Disease Vaccine Market, By Type, 2018 - 2030 (USD Million)
• Table 122 Kuwait Respiratory Disease Vaccine Market, By Age Group, 2018 - 2030 (USD Million)
• Table 123 Kuwait Respiratory Disease Vaccine Market, By Infection, 2018 - 2030 (USD Million)
• Table 124 Kuwait Respiratory Disease Vaccine Market, By Distribution Channel, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 Respiratory disease vaccine market segmentation
• Fig. 2 Data analysis models
• Fig. 3 Market formulation and validation
• Fig. 4 Data validating & publishing
• Fig. 5 Market research process
• Fig. 6 Information procurement
• Fig. 7 Primary research
• Fig. 8 Value-chain-based sizing & forecasting
• Fig. 9 QFD modelling for market share assessment
• Fig. 10 Market formulation & validation
• Fig. 11 Commodity flow analysis
• Fig. 12 Market outlook
• Fig. 13 Segment snapshot-1
• Fig. 14 Segment snapshot-2
• Fig. 15 Competitive landscape snapshot
• Fig. 16 Market trends & outlook
• Fig. 17 Porter's five force analysis
• Fig. 18 PESTEL analysis
• Fig. 19 Respiratory disease vaccine market: Type outlook key takeaways
• Fig. 20 Respiratory disease vaccine market: Type movement analysis
• Fig. 21 Viral vaccine market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 22 Bacterial vaccine market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 23 Combination vaccine market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 24 Respiratory disease vaccine market: Age Group outlook key takeaways
• Fig. 25 Respiratory disease vaccine market: Age Group movement analysis
• Fig. 26 Pediatric market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 27 Adult market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 28 Respiratory disease vaccine market: Infection outlook key takeaways
• Fig. 29 Respiratory disease vaccine market: Infection movement analysis
• Fig. 30 COVID-19 market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 31 Influenza market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 32 Respiratory Syncytial Virus (RSV) market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 33 Pneumonia market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 34 Others market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 35 Respiratory disease vaccine market: Distribution Channel outlook key takeaways
• Fig. 36 Respiratory disease vaccine market: Distribution Channel movement analysis
• Fig. 37 Hospital & Retail Pharmacies market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 38 Government Suppliers market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 39 Others market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 40 Regional marketplace outlook, 2024 & 2030 (USD million)
• Fig. 41 Regional marketplace: Key takeaways
• Fig. 42 North America Respiratory disease vaccine market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 43 Key country dynamics
• Fig. 44 U.S. Respiratory disease vaccine market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 45 Key country dynamics
• Fig. 46 Canada respiratory disease vaccine market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 47 Key country dynamics
• Fig. 48 Mexico respiratory disease vaccine market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 49 Europe respiratory disease vaccine market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 50 Key country dynamics
• Fig. 51 UK respiratory disease vaccine market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 52 Key country dynamics
• Fig. 53 Germany respiratory disease vaccine market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 54 Key country dynamics
• Fig. 55 France respiratory disease vaccine market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 56 Key country dynamics
• Fig. 57 Spain respiratory disease vaccine market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 58 Key country dynamics
• Fig. 59 Italy respiratory disease vaccine market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 60 Key country dynamics
• Fig. 61 Denmark respiratory disease vaccine market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 62 Key country dynamics
• Fig. 63 Sweden respiratory disease vaccine market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 64 Key country dynamics
• Fig. 65 Norway respiratory disease vaccine market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 66 Asia Pacific respiratory disease vaccine market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 67 Key country dynamics
• Fig. 68 Japan respiratory disease vaccine market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 69 Key country dynamics
• Fig. 70 China respiratory disease vaccine market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 71 Key country dynamics
• Fig. 72 India respiratory disease vaccine market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 73 Key country dynamics
• Fig. 74 Australia respiratory disease vaccine market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 75 Key country dynamics
• Fig. 76 South Korea respiratory disease vaccine market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 77 Key country dynamics
• Fig. 78 Thailand respiratory disease vaccine market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 79 Key country dynamics
• Fig. 80 Latin America respiratory disease vaccine market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 81 Brazil respiratory disease vaccine market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 82 Argentina respiratory disease vaccine market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 83 Middle East & Africa respiratory disease vaccine market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 84 South Africa respiratory disease vaccine market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 85 Saudi Arabia respiratory disease vaccine market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 86 UAE respiratory disease vaccine market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 87 Kuwait respiratory disease vaccine market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 88 Market participant categorization
• Fig. 89 respiratory disease vaccine market position analysis, 2024
• Fig. 90 Strategic framework

Respiratory Disease Vaccine Market Growth & Trends:

The respiratory disease vaccine market size is estimated to reach USD 70.30 billion by 2030, expanding at a CAGR of 2.90% from 2025 to 2030, according to a new report by Grand View Research, Inc. The growth of the respiratory disease vaccine market is attributable to increasing awareness associated with the importance of vaccination, the rising incidence of respiratory infections, and advancements in vaccine technology. Moreover, the COVID-19 pandemic has brought significant traction to the importance of respiratory vaccines which has further accelerated the market.

Respiratory vaccines, particularly those targeting influenza and pneumonia, are vital in reducing the burden on healthcare systems and minimizing the risk of co-infections with COVID-19. In order to prevent the spread of the virus and prevent the occurrence of outbreaks healthcare providers have been focusing on vaccination to protect individuals against respiratory pathogens like influenza. In recent years, the respiratory vaccine market has witnessed substantial growth attributed to advancements in vaccine technology, specifically in the development of vaccines targeting SARS-CoV-2. The successful development, approval, and deployment of COVID-19 vaccines have demonstrated the capacity of the scientific community to respond rapidly to respiratory threats and have paved the way for future advancements in respiratory vaccine research and development.

Moreover, government backing and surveillance at both national and global levels to monitor the availability, dissemination, and implementation of influenza vaccines is a crucial factor driving the growth of the market. Additionally, increased investments by prominent key players with a major focus on the introduction of novel vaccines into the market have contributed to the growth of the market. For instance, Pfizer recently disclosed their plans to commence Phase 3 clinical trials for their mRNA-based influenza vaccine in September 2022. This trial will involve a cohort of 25,000 individuals aged 18 and above from the U.S.

Furthermore, key players involved in developing and formulating various respiratory disease vaccines are focusing on collaborations and partnerships to develop novel vaccines and to maintain their competitive position in the market. In addition, increasing interest in plant-based medicines owing to natural remedies offered by them is expected to boost the market over the forecast period. Moreover, a number of players are involved in geographic expansion and distribution to meet the rising demand for medicinal products. For instance, in May 2023, Pfizer Inc. received FDA approval for ABRYSVO, a RSV vaccine for the prevention of lower respiratory tract disease caused by RSV in the elderly population above the age of 60 years.

Respiratory Disease Vaccine Market Report Highlights:

• Based on type, the viral vaccine segment held the largest market share of 54.84% in 2024 owing to the increasing prevalence of viral respiratory conditions
• Based on age group, the pediatric segment is expected to show the fastest growth rate over the forecast period owing to the rising formulation of vaccines for the pediatric population
• On the basis of infection, The COVID-19 segment held the largest market share of 40.03% in 2024 due to the growing need for the development of a vaccine to stop the spread of the COVID-19 virus
• Key players operating in the market are constantly focusing on geographical expansion and product launches to maintain their presence
• North America's respiratory disease vaccine market is expected to grow strongly over the forecast period which can be attributed to the presence of key players, rising healthcare infrastructure, growing cases of chronic disorders, and availability of proper vaccination service

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Market Definitions
• 1.3. Research Methodology
  • 1.3.1. Information Procurement
  • 1.3.2. Information or Data Analysis
  • 1.3.3. Market Formulation & Data Visualization
  • 1.3.4. Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. Respiratory Disease Vaccine Market Variables, Trends, & Scope

• 3.1. Market Introduction/Lineage Outlook
• 3.2. Market Size and Growth Prospects (USD Million)
• 3.3. Market Dynamics
  • 3.3.1. Market Drivers Analysis
  • 3.3.2. Market Restraints Analysis
• 3.4. Respiratory Disease Vaccine Market Analysis Tools
  • 3.4.1. Porter's Analysis
    • 3.4.1.1. Bargaining power of the suppliers
    • 3.4.1.2. Bargaining power of the buyers
    • 3.4.1.3. Threats of substitution
    • 3.4.1.4. Threats from new entrants
    • 3.4.1.5. Competitive rivalry
  • 3.4.2. PESTEL Analysis
    • 3.4.2.1. Political landscape
    • 3.4.2.2. Economic and Social landscape
    • 3.4.2.3. Technological landscape
    • 3.4.2.4. Environmental landscape
    • 3.4.2.5. Legal landscape

Chapter 4. Respiratory Disease Vaccine Market: Type Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Respiratory Disease Vaccine Market: Type Movement Analysis, 2024 & 2030 (USD Million)
• 4.3. Viral Vaccine
  • 4.3.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.4. Bacterial Vaccine
  • 4.4.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.5. Combination Vaccine
  • 4.5.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Respiratory Disease Vaccine Market: Age Group Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Respiratory Disease Vaccine Market: Age Group Movement Analysis, 2024 & 2030 (USD Million)
• 5.3. Pediatric
  • 5.3.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.4. Adult
  • 5.4.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Respiratory Disease Vaccine Market: Infection Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. Respiratory Disease Vaccine Market: Infection Movement Analysis, 2024 & 2030 (USD Million)
• 6.3. COVID-19
  • 6.3.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.4. Influenza
  • 6.4.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.5. Respiratory Syncytial Virus (RSV)
  • 6.5.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.6. Pneumonia
  • 6.6.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.7. Others
  • 6.7.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Respiratory Disease Vaccine Market: Distribution Channel Estimates & Trend Analysis

• 7.1. Segment Dashboard
• 7.2. Respiratory Disease Vaccine Market: Distribution Channel Movement Analysis, 2024 & 2030 (USD Million)
• 7.3. Hospital & Retail Pharmacies
  • 7.3.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.4. Government Suppliers
  • 7.4.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.5. Others
  • 7.5.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Respiratory Disease Vaccine Market: Regional Estimates & Trend Analysis

• 8.1. Respiratory Disease Vaccine Market Share, By Region, 2024 & 2030, USD Million
• 8.2. North America
  • 8.2.1. North America Respiratory Disease Vaccine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.2.2. U.S.
    • 8.2.2.1. U.S. Respiratory Disease Vaccine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.2.3. Canada
    • 8.2.3.1. Canada Respiratory Disease Vaccine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.2.4. Mexico
    • 8.2.4.1. Mexico Respiratory Disease Vaccine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 8.3. Europe
  • 8.3.1. Europe Respiratory Disease Vaccine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.3.2. UK
    • 8.3.2.1. UK Respiratory Disease Vaccine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.3.3. Germany
    • 8.3.3.1. Germany Respiratory Disease Vaccine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.3.4. France
    • 8.3.4.1. France Respiratory Disease Vaccine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.3.5. Italy
    • 8.3.5.1. Italy Respiratory Disease Vaccine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.3.6. Spain
    • 8.3.6.1. Spain Respiratory Disease Vaccine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.3.7. Denmark
    • 8.3.7.1. Denmark Respiratory Disease Vaccine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.3.8. Sweden
    • 8.3.8.1. Sweden Respiratory Disease Vaccine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.3.9. Norway
    • 8.3.9.1. Norway Respiratory Disease Vaccine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 8.4. Asia Pacific
  • 8.4.1. Asia Pacific Respiratory Disease Vaccine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.4.2. Japan
    • 8.4.2.1. Japan Respiratory Disease Vaccine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.4.3. China
    • 8.4.3.1. China Respiratory Disease Vaccine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.4.4. India
    • 8.4.4.1. India Respiratory Disease Vaccine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.4.5. Australia
    • 8.4.5.1. Australia Respiratory Disease Vaccine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.4.6. South Korea
    • 8.4.6.1. South Korea Respiratory Disease Vaccine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.4.7. Thailand
    • 8.4.7.1. Thailand Respiratory Disease Vaccine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 8.5. Latin America
  • 8.5.1. Latin America Respiratory Disease Vaccine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5.2. Brazil
    • 8.5.2.1. Brazil Respiratory Disease Vaccine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5.3. Argentina
    • 8.5.3.1. Argentina Respiratory Disease Vaccine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 8.6. Middle East and Africa
  • 8.6.1. Middle East and Africa Respiratory Disease Vaccine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.6.2. South Africa
    • 8.6.2.1. South Africa Respiratory Disease Vaccine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.6.3. Saudi Arabia
    • 8.6.3.1. South Africa Respiratory Disease Vaccine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.6.4. UAE
    • 8.6.4.1. UAE Respiratory Disease Vaccine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.6.5. Kuwait
    • 8.6.5.1. Kuwait Respiratory Disease Vaccine Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Recent Developments & Impact Analysis by Key Market Participants
• 9.2. Company Categorization
• 9.3. Company Heat Map Analysis
• 9.4. Company Profiles
  • 9.4.1. GSK plc.
    • 9.4.1.1. Participant's Overview
    • 9.4.1.2. Financial Performance
    • 9.4.1.3. Product Benchmarking
    • 9.4.1.4. Recent Developments/ Strategic Initiatives
  • 9.4.2. Johnson & Johnson Services, Inc.
    • 9.4.2.1. Participant's Overview
    • 9.4.2.2. Financial Performance
    • 9.4.2.3. Product Benchmarking
    • 9.4.2.4. Recent Developments/ Strategic Initiatives
  • 9.4.3. Pfizer Inc.
    • 9.4.3.1. Participant's Overview
    • 9.4.3.2. Financial Performance
    • 9.4.3.3. Product Benchmarking
    • 9.4.3.4. Recent Developments/ Strategic Initiatives
  • 9.4.4. Sanofi
    • 9.4.4.1. Participant's Overview
    • 9.4.4.2. Financial Performance
    • 9.4.4.3. Product Benchmarking
    • 9.4.4.4. Recent Developments/ Strategic Initiatives
  • 9.4.5. Serum Institute of India Pvt. Ltd.
    • 9.4.5.1. Participant's Overview
    • 9.4.5.2. Financial Performance
    • 9.4.5.3. Product Benchmarking
    • 9.4.5.4. Recent Developments/ Strategic Initiatives
  • 9.4.6. SINOVAC
    • 9.4.6.1. Participant's Overview
    • 9.4.6.2. Financial Performance
    • 9.4.6.3. Product Benchmarking
    • 9.4.6.4. Recent Developments/ Strategic Initiatives
  • 9.4.7. Bavarian Nordic
    • 9.4.7.1. Participant's Overview
    • 9.4.7.2. Financial Performance
    • 9.4.7.3. Product Benchmarking
    • 9.4.7.4. Recent Developments/ Strategic Initiatives
  • 9.4.8. Merck & Co., Inc.
    • 9.4.8.1. Participant's Overview
    • 9.4.8.2. Financial Performance
    • 9.4.8.3. Product Benchmarking
    • 9.4.8.4. Recent Developments/ Strategic Initiatives
  • 9.4.9. AstraZeneca
    • 9.4.9.1. Participant's Overview
    • 9.4.9.2. Financial Performance
    • 9.4.9.3. Product Benchmarking
    • 9.4.9.4. Recent Developments/ Strategic Initiatives
  • 9.4.10. EMERGENT
    • 9.4.10.1. Participant's Overview
    • 9.4.10.2. Financial Performance
    • 9.4.10.3. Product Benchmarking
    • 9.4.10.4. Recent Developments/ Strategic Initiatives
  • 9.4.11. Novavax
    • 9.4.11.1. Participant's Overview
    • 9.4.11.2. Financial Performance
    • 9.4.11.3. Product Benchmarking
    • 9.4.11.4. Recent Developments/ Strategic Initiatives
  • 9.4.12. INOVIO Pharmaceuticals
    • 9.4.12.1. Participant's Overview
    • 9.4.12.2. Financial Performance
    • 9.4.12.3. Product Benchmarking
    • 9.4.12.4. Recent Developments/ Strategic Initiatives
  • 9.4.13. Moderna, Inc.
    • 9.4.13.1. Participant's Overview
    • 9.4.13.2. Financial Performance
    • 9.4.13.3. Product Benchmarking
    • 9.4.13.4. Recent Developments/ Strategic Initiatives